CoChat

Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Objective: Sustained inflammation originating from macrophages is a driving force of fibrosis progression and resolution. Monoacylglycerol lipase (MAGL) is the rate-limiting enzyme in the degradation of monoacylglycerols. It is a proinflammatory enzyme that metabolises 2-arachidonoylglycerol, an endocannabinoid receptor ligand, into arachidonic acid. Here, we investigated the impact of MAGL on inflammation and fibrosis during chronic liver injury. Design: C57BL/6J mice and mice with global invalidation of MAGL (MAGL-/-), or myeloid-specific deletion of either MAGL (MAGL Mye-/-), ATG5 (ATG Mye-/-) or CB2 (CB2 Mye-/-), were used. Fibrosis was induced by repeated carbon tetrachloride (CCl 4) injections or bile duct ligation (BDL). Studies were performed on peritoneal or bone marrow-derived macrophages and Kupffer cells. Results: MAGL-/- or MAGL Mye-/- mice exposed to CCl 4 or subjected to BDL were more resistant to inflammation and fibrosis than wild-type counterparts. Therapeutic intervention with MJN110, an MAGL inhibitor, reduced hepatic macrophage number and inflammatory gene expression and slowed down fibrosis progression. MAGL inhibitors also accelerated fibrosis regression and increased Ly-6C low macrophage number. Antifibrogenic effects exclusively relied on MAGL inhibition in macrophages, since MJN110 treatment of MAGL Mye-/- BDL mice did not further decrease liver fibrosis. Cultured macrophages exposed to MJN110 or from MAGL Mye-/- mice displayed reduced cytokine secretion. These effects were independent of the cannabinoid receptor 2, as they were preserved in CB2 Mye-/- mice. They relied on macrophage autophagy, since anti-inflammatory and antifibrogenic effects of MJN110 were lost in ATG5 Mye-/- BDL mice, and were associated with increased autophagic flux and autophagosome biosynthesis in macrophages when MAGL was pharmacologically or genetically inhibited. Conclusion: MAGL is an immunometabolic target in the liver. MAGL inhibitors may show promising antifibrogenic effects during chronic liver injury.

Overview

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2018-316137

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. 10.1016/j.celrep.2015.06.075 · DOI · Paper page

Cited by

See all 94

Metadata

Authors
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., Mansouri, A., Brouillet, A., Tardelli, M., Weiss, E., Le Faouder, P., Guillou, H., Cravatt, B. F., Moreau, R., Trauner, M., & Lotersztajn, S.
Affiliations
  • Inserm (FR)
  • Medical University of Vienna (AT)
  • Université Toulouse III - Paul Sabatier (FR)
  • Scripps Research Institute (US)
Corresponding author
Lotersztajn, Sophie
Venue
Gut
Publisher
BMJ
Published
2018-10-09
Volume
68
Issue
3
Pages
522-532
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2897753115
Cited by
91
References
42
Citations by year
2026: 9 · 2025: 12 · 2024: 8 · 2023: 14 · 2022: 7 · 2021: 16 · 2020: 15 · 2019: 8 · 2018: 2
FWCI
6.48
Type
journal article
Language
en
Open access
closed
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • Austrian Science Funds
  • Association Française pour l’Etude du Foie
  • Fondation pour la Recherche Médicale
  • Institut National de la Santé et de la Recherche Médicale
  • Agence Nationale de la Recherche
  • Programme PHC Cedre
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
monoacylglycerol lipase, MAGL inhibition, liver fibrosis, liver inflammation, macrophages, Kupffer cells, 2-arachidonoylglycerol, endocannabinoids, autophagy, ATG5, CB2 receptor, chronic liver injury, bile duct ligation, carbon tetrachloride, immunometabolism
MeSH terms
Animals, Anti-Inflammatory Agents, Autophagy, Carbamates, Carbon Tetrachloride, Cell Count, Cells, Cultured, Drug Evaluation, Preclinical, Hydrolases, Liver, Liver Cirrhosis, Experimental, Macrophages, Male, Mice, Inbred C57BL, Monoacylglycerol Lipases, Succinimides, Cytokines, Mice, Knockout, Disease Progression, Inflammation Mediators, Receptor, Cannabinoid, CB2, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. https://app.cochat.ai/papers/10.1136/gutjnl-2018-316137
The paper
Habib, A., Chokr, D., Wan, J., Hegde, P., Mabire, M., Siebert, M., Ribeiro-Parenti, L., Le Gall, M., Lettéron, P., Pilard, N., Mansouri, A., Brouillet, A., Tardelli, M., Weiss, E., Le Faouder, P., Guillou, H., Cravatt, B. F., Moreau, R., Trauner, M., & Lotersztajn, S. (2019). Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. Gut. https://doi.org/10.1136/gutjnl-2018-316137

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.